Therapy of alopecia areata: on the cusp and in the future.
Over the past decade, basic research has established alopecia areata as a T cell-mediated autoimmune disease and has clarified many of its genetic, cellular, and molecular aspects. Perifollicular and intrafollicular mononuclear cell infiltrates directed at anagen hair bulbs are characteristic and striking histologic features in early alopecia areata. The inflammatory infiltrate is composed predominantly of activated CD4+ and CD8+ T cells, together with macrophages and Langerhans cells. The initiation phase of alopecia areata is mediated by type 1 cytokines, including interleukin-2, interferon-gamma, and tumor necrosis factor-alpha. Like other diseases with a strong autoimmune component, alopecia areata has associated with it specific human leukocyte antigens, which determine susceptibility, severity, chronicity, and resistance. New topical immunomodulating drugs and biologic therapies that have been developed, or that are in development, for the treatment of other immune-mediated inflammatory skin diseases will likely be effective in alopecia areata as well. The present discussion addresses the treatment of alopecia areata within the framework of these new modalities.
Department of Dermatology, University of California, San Francisco, California 94117, USA. vhprice@orca.ucsf.edu
Vera H
VH
Price
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000506:Alopecia Areata / Q000628:therapy*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use; D003880:Dermatology / Q000639:trends*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D001688:Biological Products; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins